<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209533</url>
  </required_header>
  <id_info>
    <org_study_id>100637</org_study_id>
    <nct_id>NCT01209533</nct_id>
  </id_info>
  <brief_title>Inhaled Iloprost in Mild Asthma</brief_title>
  <official_title>Inhaled Iloprost in Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if inhaled iloprost given four times daily can
      improve symptoms and lung function in adults with mild asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Animal studies have suggested that prostacyclin may downregulate allergic inflammation, thus
      providing the scientific basis for trials of inhaled prostacyclin agonists such as iloprost
      for the treatment of asthma. This study will examine the tolerability of four times daily
      iloprost on asthma symptoms and pulmonary function over a two week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD20FEV1 methacholine</measure>
    <time_frame>two weeks</time_frame>
    <description>Provocative dose of methacholine resulting in a 20% fall in FEV1 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>asthma related symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Asthma quality of life questionnaire; Juniper</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma control</measure>
    <time_frame>4wks</time_frame>
    <description>Juniper asthma control test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>2wks</time_frame>
    <description>Forced expiratory flow in one second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>2 wks</time_frame>
    <description>Measurement of exhaled nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 17</measure>
    <time_frame>2wks</time_frame>
    <description>ELISA measurement of serum interleukin 17</description>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost</intervention_name>
    <description>Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days</description>
    <other_name>Ventavis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-60

          2. History of asthma controlled by inhaled rescue medication (albuterol, levalbuterol
             etc) and/or inhaled corticosteroids

          3. Ability to give informed consent

          4. Ability to perform pulmonary function tests

          5. Ability to tolerate the initial Ventavis inhalation

          6. Ability to comply with the study protocol

        Exclusion Criteria:

          1. Cigarette smoking

          2. Concomitant serious disease such as diabetes, hypertension, coronary heart disease,
             other lung disease, cancer (other than skin cancer)

          3. Pregnancy or lack of contraception (hormonal or barrier)

          4. Allergies or intolerance to inhaled iloprost

          5. Participation in other ongoing research studies

          6. Any psychological problem that the investigators believe might interfere with the
             conduct of the investigation.

          7. Cigarette smoking

          8. History of bleeding disorder, use of anticoagulants

          9. Viral upper respiratory tract infection within the last 6 weeks

         10. Table of upper limit for steroid use Beclomethasone dipropionate HFA-MDI 480
             Budesonide DPI 1200 Flunisolide HFA-MDI 640 Fluticasone HFA-MDI 440 Fluticasone DPI
             500 Mometasone DPI 440 Triamcinolone 1500 (Table adapted from EPR3, daily doses are in
             micrograms) Asthmatics requiring higher doses of inhaled corticosteroids than those
             given above, or using oral steroids, leukotriene modifiers, mast cell stabilizers,
             omalizumab, theophylline or long acting beta agonists will be excluded.

         11. .Any screening laboratory blood test value outside the normal range will exclude the
             individual from the study, though an isolated abnormal value could be retested at an
             interval of no less than a week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Sheller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>J.R. Sheller, M.D.</name_title>
    <organization>Vanderbilt University</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

